Pasireotide vs PT-141
Overview
Pasireotide and PT-141 are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Pasireotide and PT-141 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | PT-141 | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 1.75 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | as needed |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Enhanced libido, improved sexual function, arousal support |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Nausea, flushing, blood pressure changes |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while PT-141 falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Pasireotide: FDA-approved. PT-141: FDA-approved.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). PT-141 is typically dosed at 1.75 mg (as needed).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and PT-141 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and PT-141?
- Pasireotide and PT-141 are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Pasireotide is FDA-approved for one or more indications, whereas PT-141 is FDA-approved for one or more indications.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is PT-141 used for?
- Sexual function peptide.
- Can you take Pasireotide and PT-141 together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and PT-141 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or PT-141 FDA-approved?
- Pasireotide is FDA-approved for one or more indications. PT-141 is FDA-approved for one or more indications.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- PT-141 — full monograph: mechanism, research, dosing & references